Allworth Financial LP Editas Medicine, Inc. Transaction History

Allworth Financial LP

  • $14 Billion
  • Q1 2024

A detailed history of Allworth Financial LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 651 shares of EDIT stock, worth $2,955. This represents 0.0% of its overall portfolio holdings.

Number of Shares
651
Previous 423 53.9%
Holding current value
$2,955
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024
BUY
$7.03 - $11.07 $1,602 - $2,523
228 Added 53.9%
651 $4,000
Q4 2023

Jan 24, 2024
SELL
$6.25 - $11.11 $237 - $422
-38 Reduced 8.24%
423 $4,000
Q3 2023

Oct 31, 2023
BUY
$6.92 - $9.31 $262 - $353
38 Added 8.98%
461 $3,000
Q2 2023

Jul 18, 2023
BUY
$6.36 - $11.47 $146 - $263
23 Added 5.75%
423 $3,000
Q1 2023

Apr 18, 2023
BUY
$7.03 - $11.53 $703 - $1,153
100 Added 33.33%
400 $2,000
Q4 2022

Jan 13, 2023
BUY
$8.32 - $13.21 $1,364 - $2,166
164 Added 120.59%
300 $0
Q3 2022

Oct 18, 2022
SELL
$12.16 - $19.42 $2,602 - $4,155
-214 Reduced 61.14%
136 $2,000
Q2 2022

Jul 13, 2022
BUY
$9.99 - $21.35 $3,496 - $7,472
350 New
350 $4,000
Q1 2022

Apr 22, 2022
SELL
$14.08 - $27.63 $1,408 - $2,763
-100 Closed
0 $0
Q4 2021

Jan 21, 2022
SELL
$26.55 - $40.57 $10,620 - $16,228
-400 Reduced 80.0%
100 $3,000
Q3 2021

Nov 02, 2021
BUY
$39.27 - $72.94 $3,927 - $7,294
100 Added 25.0%
500 $21,000
Q2 2021

Aug 02, 2021
SELL
$31.29 - $56.64 $9,387 - $16,992
-300 Reduced 42.86%
400 $23,000
Q1 2021

Apr 29, 2021
BUY
$39.71 - $90.58 $3,971 - $9,058
100 Added 16.67%
700 $29,000
Q3 2020

Nov 03, 2020
BUY
$28.06 - $37.16 $16,836 - $22,295
600 New
600 $17,000

Others Institutions Holding EDIT

# of Institutions
243
Shares Held
69.3M
Call Options Held
564K
Put Options Held
428K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $312M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email